The Economic Burden of Chronic Obstructive Pulmonary Disease in Greece
Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and death worldwide, imposing a substantial socioeconomic burden on societies and patients due to the long-term management required.
To assess the economic burden of COPD in Greece and its potential determinants.
A population-based, random-digit dialled, telephone nationwide survey was conducted to recruit patients with COPD in Greece (N = 351). A structured questionnaire was used to collect data. The total annual cost per patient from a societal perspective was calculated.
The mean (95% CI) annual total cost per patient for the management of COPD from a societal perspective was €2150 (€1879–€2443). The total annual cost was mainly driven by the medication cost (36.1%), followed by the cost of hospitalizations (26.7%) and long-term oxygen therapy (13.8%). Multiple generalized linear model revealed that age, COPD Assessment Test (CAT) score and exacerbations were independently associated with the total annual cost.
Investment in interventions aiming at delaying progression of disease, preventing acute exacerbations, and managing chronic symptoms are required to reduce the overall economic burden of COPD in Greece.
GK designed the study, conducted the analyses, interpreted the results, and wrote the manuscript. NM, GH, and TV contributed to questionnaire development, results interpretation, and manuscript writing.
Compliance with Ethical Standards
Data availability statement
The dataset along with the software code will be provided upon request.
Conflict of interest
The authors Georgia Kourlaba, Georgios Hillas, Theodoros Vassilakopoulos, and Nikos Maniadakis declare that they have no conflicts of interest.
This study was funded by the Hellenic Thoracic Society.
According to the Greek legislation (Law 2328/1995, Presidential Decree 310/1996, Law 3603/2007, Law 2472/1997, Law 3471/2006) there is no need for ethical approval for telephone surveys such the one presented here (Association of Opinion Polls and Survey Organisations—http://www.sedea.gr).
Verbal informed consent was obtained from all individual participants included in the study.
- 9.Kourlaba G, Hillas G, Vassilakopoulos T, Maniadakis N. The disease burden of chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2016 (in press).Google Scholar
- 13.Landis SH, Muellerova H, Mannino DM, Menezes AM, Han MK, van der Molen T, et al. Continuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012–2013. Int J Chron Obstruct Pulmon Dis. 2014;9:597–611.Google Scholar
- 17.Greek Ministry of Health M. Drug price bulletin. 2015.Google Scholar
- 18.International Monetary Fund. World Economic Outlook Database. 2013. http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/index.aspx.
- 19.WHO. Policy dialogue to reduce out-of-pocket payments for health in Greece. 2018. http://www.euro.who.int/en/countries/greece/news/news/2018/5/policy-dialogue-to-reduce-out-of-pocket-payments-for-health-in-greece.
- 26.Kim J, Lee TJ, Kim S, Lee E. The economic burden of chronic obstructive pulmonary disease from 2004 to 2013. J Med Econ. 2015;2015:1–8.Google Scholar
- 28.Migdalis I, Rombopoulos G, Hatzikou M, Manes C, Kypraios N, Tentolouris N. The cost of managing Type 2 diabetes mellitus in Greece: a retrospective analysis of 10-year patient level data “The HERCULES Study”. Int J Endocrinol. 2015;2015:520759.Google Scholar